through innovative new drug developments
- HOME
- Company
- About the Company
We are a biotech company developing new treatments for patients resistant to existing
therapies based on innovative new drug modalities such as antibody-drug conjugate(ADC).
Based on our strong R&D capabilities, we have built our next-generation ADC platform PINOT-ADC™ independently and have been working with various partners to research new ADC anticancer treatments. In addition, clinical development and commercialization of NTX-301, a targeted anticancer drug for blood/solid cancer, and NTX-101, a treatment for glaucoma, are underway.
-
ADC Platform
Next Generation ADC Platform Technology
Payload and Linker that can overcome resistance
Next-Gen Targeted
Anticancer TherapyClinical safety and efficacy has been confirmed for NTX-301
Dual action, exerting powerful anticancer effect
-
Multi-mechanism,
multi-target
Anticancer drugs -
Global Leading Biotech for
Novel Anticancer
Treatment